CA-FOCAL-SYSTEMS
16.3.2022 18:58:07 CET | Business Wire | Press release
On their mission to automate and optimize brick and mortar retail with state-of-the-art AI and deep learning, Focal Systems is proud to announce the launch of the world’s first “Self-Driving Store”-Operating System powered by computer vision and AI, called FocalOS. After 7 years hardening the platform with the largest retailers in the world, Focal's “Self-Driving Store”-Operating System is now Generally Available.
Enabled by AI-powered Shelf Cameras, FocalOS leverages computer vision and deep learning technology to provide real-time shelf digitization. This digitization feeds FocalOS, which automates order writing and ordering, directs stockers to double their productivity, optimizes category management on a per store basis, manages e-comm platforms to eliminate substitutions, tracks productivity per associate to drive further efficiencies, and much more. With FocalOS, corporate leaders can "teleport" into any store from anywhere in the world in seconds to see exactly what their shelves look like and how their stores are performing.
Major retailers have proven >50x ROI with FocalOS, making this the most profitable investment in all of retail technology.
Francois Chaubard, Founder and CEO, will unveil this solution in depth at the FMI Midwinter Conference in Orlando, Fla. on March 29.
Retailers have incredibly challenging jobs. Managing thousands of SKUs, employees, stores and ecommerce, while facing rising labor and supply chain costs and the evergreen battle for market share. Since 2015 our team has worked with leading global retailers to invent and implement AI solutions that drive true innovation, transformative financial returns and happy customers.
-Francois Chaubard - Founder/CEO Focal Systems
Focal has worked with leading retailers across North America, Europe and Australia and deployed more than 50,000 cameras worldwide. This launch enables retailers the ability to run fully automated “Self-Driving Stores" that achieve unprecedented labor efficiencies and sales growth just by setting the store on "Cruise Control" and letting the AI take it from there.
We’re always striving for more ways to improve the shopping experience for our customers. Focal is helping us use technology to improve our on-shelf customer availability, so our customers can find what they are looking for each time they choose to shop in-store with us.”
-Sam Wankowski - Chief Operations Officer, Walmart Canada
About Focal Systems
Founded in 2015 in San Francisco out of Stanford’s Computer Vision Lab, Focal Systems is the industry leader in retail automation. Our mission is to automate and optimize brick and mortar retail with state of the art deep learning and AI. We have pioneered the world’s first “Self-Driving Store”-Operating System that revolutionizes how stores are run. Focal has raised more than $40m to date, and scaled their solutions to three continents and hundreds of stores, with thousands of cameras deployed. The Focal team is a carefully selected group of retail operations and AI experts who together have designed the next generation of operating systems for brick and mortar retail that leverages state-of-the-art AI and retail best practices to automate and optimize brick and mortar and on-line stores today.
Learn more at: https://focal.systems
View source version on businesswire.com: https://www.businesswire.com/news/home/20220316005906/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom